Oyvind Dahle
Senior Counsel
Oyvind Dahle聽works with organizations to provide patent protection of technologies, such as chemical compounds and polymers, pharmaceutical compositions and delivery systems; immunotherapeutics using engineered antigen binding proteins, such as multispecific immunoglobulin-based molecules and chimeric antigen receptor T cell receptors; stem cell therapy; genetic modification technologies, such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR); artificial intelligence-based drug discovery and diagnostics; diagnostic methods, such as liquid biopsy; next-generation sequencing (NGS), multiplex PCR, single-cell sequencing, and medical devices. In addition to drafting and prosecuting patents, Oyvind has experience with providing patentability, invalidity, and freedom-to-operate opinions, and representing patent owners on appeals and inter partes reviews before the Patent Trial and Appeal Board (PTAB). He is a member of the firm鈥檚 Chemical, Biotechnology & Pharmaceutical Practice.
Oyvind joined 番茄社区; Lardner as an associate in 2016, and prior to that, he externed at the U.S. Patent and Trademark Office鈥檚 Office of Patent Legal Administration, where he gained experience in patent examination procedures and assessments.
Oyvind also has extensive experience as a scientist and has a Ph.D. in biochemistry. In particular, he has worked at Leidos, Inc. as a scientist, at the National Cancer Institute鈥檚 Laboratory of Protein Dynamics and Signaling as a research fellow, and at the National Cancer Institute in its Experimental Immunology Branch as a postdoctoral fellow. At the National Cancer Institute, Oyvind conducted research on the development and function of the immune system, the pathology of cancer such as multiple myeloma, stem cell function and applications, and early embryonic development.
Presentations and Publications
- Author, 鈥淕LP-1 Receptor Agonists and Patent Strategy: Securing Patent Protection for New Use of Old Drugs,鈥 Health Care Law Today (March 12, 2025)
- Author, 鈥淐ancer Drugs: Strategies For Patenting Antibody-Drug Conjugate Inventions,鈥 Health Care Law Today (April 29, 2024)
- Author, 鈥淭he Absurdity of Patent Ineligible Categories: The Discrepancy Between the Ariosa and Cellzdirect Decisions Highlights the Problems Created by Formalistic Adjudication of Patent Eligibility,鈥 Wake Forest Journal of Business and Intellectual Property Law, Vol. 17 No. 1 (2016)
- Co-author, 鈥淚nhibiting Smad2/3 Signaling in Pluripotent Mouse Embryonic Stem Cells Enhances Endoderm Formation by Increasing Transcriptional Priming of Lineage-Specifying Target Genes,鈥 Developmental Dynamics, Vol. 245 Issue 7 (2016)
- Co-author, 鈥淧olycomb Determines Responses to Smad2/3 Signaling in Embryonic Stem Cell Differentiation and in Reprogramming,鈥 Stem Cells, Vol. 31 Issue 8 (2013)
- Presenter, 鈥淓pigenetics in Development Polycomb Determines Smad2/3 Responses During Cell Fate Transitions in Stem Cell Differentiation and Reprogramming,鈥 National Institutes of Health, Maryland (2013)
- Co-author, 鈥淣odal Signaling Recruits Histone Demethylase Jmjd3 to Counteract Polycomb Repression at Target Genes,鈥 Science Signaling, Vol. 3 Issue 127 (2010)
- Co-author, 鈥淔LASH Acts as a Co-activator of the Transcription Factor c-Myb and Localizes to Active RNA Polymerase II Foci,鈥 Oncogene, Vol. 27 (2008)
- Co-author, 鈥淭he Chromatin Remodeling Factor Mi-2 Acts as a Novel Co-activator for Human c-Myb,鈥 The Journal of Biological Chemistry, Vol. 282 (2007)
- Co-author, 鈥淐oreceptor Signal Strength Regulates Positive Selection but Does Not Determine CD4/CD8 Lineage Choice in a Physiologic in Vivo Model,鈥 The Journal of Immunology, Vol. 177 Issue 10 (2006)
- Co-author, 鈥淧ML Mediates IFN-alpha-induced Apoptosis in Myeloma by Regulating TRAIL Induction,鈥 Blood, Vol. 105 (2005)
- Co-author, 鈥渃-Myb Associates with PML in Nuclear Bodies in Hematopoietic Cells,鈥 Experimental Cell Research, Vol. 297 Issue 1 (2004)
- Co-author, 鈥淭ransactivation Properties of c-Myb Are Critically Dependent on Two SUMO-1 Acceptor Sites That Are Conjugated in a PIASy Enhanced Manner,鈥 European Journal of Biochemistry, Vol. 270 (2003)
- Co-author, 鈥淛AB1/CSN5 Interacts with the GAL4 DNA Binding Domain: A Note of Caution About Two-Hybrid Interactions,鈥 Biochimie, Vol. 83 Issue 10 (2001)
Languages
- Norwegian
Patent analysis is increasingly shaping AI-driven target and drug candidate selection
/Passle/63109459f636e905f41c4854/SearchServiceImages/2026-02-04-13-55-21-426-69834fc9d571d0784502c00b.jpg)
A New Humanized Fc Mouse Model to De-Risk and Scale Antibody Programs, and Enable Innovation
/Passle/63109459f636e905f41c4854/SearchServiceImages/2025-12-04-13-47-23-365-693190eb3335f319e5bf471a.jpg)
FDA Guidance on Biosimilars Highlights Glycosylation Profiling and Increases the Strategic Value of Patents Covering Antibodies Defined by Glycosylation
/Passle/67196104ea6deed3d1072b7a/MediaLibrary/Images/2025-05-15-14-32-24-265-6825faf86e173c9cc1d8c7e6.jpg)
New Drug Approvals: 鈥淗uman Organ-on-a-Chip鈥 GAO Report Supports Innovation and Regulatory Policy for Non-Animal Models
/Passle/63109459f636e905f41c4854/SearchServiceImages/2025-08-20-23-19-32-993-68a65804c21a05ca9015de72.jpg)